The Impact of the Medicare Part D Prescription Benefit on Generic Drug Use

[1] Doherty RB(2004)Assessing the new Medicare prescription drug law Ann Intern Med 141 391-395

[2] Heiss F(2006)Who failed to enroll in Medicare Part D, and why? Early results Health Affairs 25 w344-w354

[3] McFadden D(2006)Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage Health Aff 26 w1-w12

[4] Winter J(2004)Medicare drug coverage and moral hazard Health Aff 23 113-122

[5] Cubanski J(2008)The impact of the Medicare Part D prescription drug benefit on drug utilization and out-of-pocket costs Annals of Internal Medicine 148 169-177

[6] Neuman P(2007)The ongoing regulation of generic drugs N Engl J Med 357 1993-1996

[7] Pauly MV(2005)Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997–2000 Ann Intern Med 142 891-897

[8] Yin W(2005)What do primary care patients think about generic drugs? International Journal of Clinical Pharmacology and Therapeutics 43 472-479

[9] Basu A(2005)Patent term extension strategies in the pharmaceutical industry Pharmaceuticals Policy and Law 6 109-122

[10] Zhang J(2007)Health spending projections through 2016: modest changes obscure Part D’s impact Health Aff 26 w242-w253

[1] Doherty RB(2004)Assessing the new Medicare prescription drug law Ann Intern Med 141 391-395

[2] Heiss F(2006)Who failed to enroll in Medicare Part D, and why? Early results Health Affairs 25 w344-w354

[3] McFadden D(2006)Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage Health Aff 26 w1-w12

[4] Winter J(2004)Medicare drug coverage and moral hazard Health Aff 23 113-122

[5] Cubanski J(2008)The impact of the Medicare Part D prescription drug benefit on drug utilization and out-of-pocket costs Annals of Internal Medicine 148 169-177

[6] Neuman P(2007)The ongoing regulation of generic drugs N Engl J Med 357 1993-1996

[7] Pauly MV(2005)Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997–2000 Ann Intern Med 142 891-897

[8] Yin W(2005)What do primary care patients think about generic drugs? International Journal of Clinical Pharmacology and Therapeutics 43 472-479

[9] Basu A(2005)Patent term extension strategies in the pharmaceutical industry Pharmaceuticals Policy and Law 6 109-122

[10] Zhang J(2007)Health spending projections through 2016: modest changes obscure Part D’s impact Health Aff 26 w242-w253